Cancer Research on Prevention and Treatment    2021, Vol. 48 Issue (07) : 714-718     DOI: 10.3971/j.issn.1000-8578.2021.20.0905
|
Prognosis of Stage ⅠB-ⅡA Cervical Squamous Cell Carcinoma Patients with Intermediate Risk Factors Treated with Adjuvant Chemotherapy Versus Concurrent Chemoradiotherapy: A Prospective Randomized Controlled Trial
PAN Zhongmian, CHEN Qi, LI Li
Department of Gynecologic Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Ministry of Education, Nanning 530021, China
Download: PDF(3371 KB)   ( 35 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Objective To compare the prognosis of stage ⅠB-ⅡA cervical squamous cell carcinoma patients with intermediate risk factrs between adjuvant chemotherapy and concurrent chemoradiotherapy, and to explore the safety and effectiveness of adjuvant chemotherapy after surgery. Methods A total of 190 patients treated at the Affiliated Cancer Hospital of Guangxi Medical University were selected and randomly divided into two groups: chemotherapy group (CT group, n=95) and concurrent chemoradiotherapy group (CCRT group, n=95). Ten patients lost to follow-up. Kaplan-Meier method and Log rank test were used for OS calculation and survival curve comparison. Cox proportional-hazards regression model was used for multivariate analysis. Results After a median follow-up of 36.7 months, 190 patients were evaluable. The incidence of G3/G4 blood system toxicity were 3.3% in CT group and 10.11% in CCRT group (P=0.019), the incidence of severe gastrointestinal toxicity were 4.4% in CT group and 17.98% in CCRT group, the incidence of radiation-related response was 22.48%. There was no significant difference in the local recurrence rate or distant recurrence rate between two groups (P>0.05). There was no statistically significant difference in PFS and OS between two groups (P>0.05). Conclusion There is no significant difference between postoperative chemotherapy and concurrent chemoradiotherapy on stage ⅠB-ⅡA cervical squamous cell carcinoma patients with intermediate risk facfors, but the adverse reactions of postoperative chemotherapy are significantly reduced compared with concurrent chemoradiotherapy.
Keywords Cervical squamous cell carcinoma      Intermediate risk factors      Chemotherapy      Concurrent chemoradiotherapy
     
ZTFLH:  R737.33  
Fund:Subject of Guangxi Scientific Research and Technology Development Plan (No. 14124004)
Issue Date: 13 July 2021
 Cite this article:   
PAN Zhongmian,CHEN Qi,LI Li. Prognosis of Stage ⅠB-ⅡA Cervical Squamous Cell Carcinoma Patients with Intermediate Risk Factors Treated with Adjuvant Chemotherapy Versus Concurrent Chemoradiotherapy: A Prospective Randomized Controlled Trial[J]. Cancer Research on Prevention and Treatment, 2021, 48(07): 714-718.
 URL:  
http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2021.20.0905
http://www.zlfzyj.com/EN/Y2021/V48/I07/714
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
PAN Zhongmian
CHEN Qi
LI Li
[1] Mabuchi S, Morishige K, Isohashi F, et al. Postoperative concurrent
nedaplatin-based chemoradiotherapy improves survival in earlystage
cervical cancer patients with adverse risk factors[J]. Gynecol Oncol, 2009, 115(3): 482-487.
[2] Song S, Song C, Kim HJ, et al. 20 year experience of postoperative
radiotherapy in ⅠB-ⅡA cervical cancer patients with intermediate
risk factors: impact of treataient period and concurrent
chemotherapy[J]. Gynecol Oncol, 2012, 124(1): 63-67.
[3] 温宏武, 黄卫平, 刘桐宇, 等. 不同辅助治疗方法对Ⅰb~Ⅱa期
子宫颈癌术后有危险因素患者预后的影响[J]. 中华妇产科杂
志, 2013, 48(12): 920-926. [Wen HW, Huang WP, Liu TY, et al.
Results of different postoperative adjuvant therapies for stage
Ⅰb-Ⅱa cervical carcinoma with risk factors[J]. Zhonghua Fu
Chan Ke Za Zhi, 2013, 48(12): 920-926.]
[4] Landoni F, ColomboA, Milani R, et al. Randomized study between
radical surgery and radiotherapy for the treatment of stage ⅠB-
ⅡA cervical cancer: 20-year update[J]. J Gynecol Oncol, 2017,
28(3): e34: 1-10.
[5] 唐秋, 屠晔强, 陈建红, 等. 同步放化疗治疗早期宫颈癌术后中危
患者的疗效分析[J]. 中华肿瘤杂志, 2018, 40(6): 462-466. [Tang
Q, Tu YQ, Chen JH, et al. Curative effect analysis of postoperative
concurrent chemoradiotherapy on early-stage cervical cancer
patients withintermediate-risk factors[J]. Zhonghua Zhong Liu Za
Zhi, 2018, 40(6): 462-466.]
[6] 吉维, 冉立, 常建英, 等. 不同治疗方式对术后伴中危因素
Ⅰ-ⅡA期宫颈癌预后影响[J]. 中华放射肿瘤学杂志, 2019,
28(5): 358-363. [Ji W, Ran L, Chang JY, et al. Effect of different
therapeutic methods on survival of stage Ⅰ-Ⅱ A cervical
cancer patients complicated with postoperative intermediate risk
factors[J]. Zhonghua Fang She Zhong Liu Xue Za Zhi, 2019,
28(5): 358-363.]
[7] Sittidilokratna K, Cheewakriangkrai C, Khunamornpong S, et al.
Recurrence patterns after radical hysterectomy in stageⅠB1-ⅡA
cervical[J]. Asian Pac J Cancer Prev, 2010, 11(2): 499-502.
[8] Lee KB, Lee JM, Ki KD, et al. Comparison ofadjuvant
chemotherapy and radiation in patients with intermediate risk
factors after radical surgery in FIGO stageⅠB-ⅡA cervical
cancer[J]. Int J Gynecol Cancer, 2008, 18(5): 1027-1031.
[9] Hosaka M, Watari H, Takeda M, et al. Treatment of cervical cancer
with adjuvant chemotherapy versus adjuvant radiotherapy after
radical hysterectomy and systematic lymphadenectomy[J]. J
Obstet Gynaecol Res, 2008, 34(4): 552-556.
[10] Ryu SY, Park SI, Nam BH, et al. Is adjuvant chemoradiotherapy
overtreatment in cervical cancer patients with intermediate risk
factors?[J]. Int J Radia Oncol Biol Physics, 2011, 79(3): 794-799.
[11] Hosaka M, Watari H, Kato T, et al. Clinical efficacy of paclitaxel/
cisplatin as an adjuvant chemotherapy for patients with cervical
cancer who underwent radical hysterectomy and systematic
lymphadenectomy[J]. J Surg Oncol, 2012, 105(6): 612-616.

Related articles from Frontiers Journals
[1] MAO Wanli, RAN Li, LI Jiehui, LI Fenghu, CHANG Jianying, MU Junyu, MEI Fan, HU Lili, DU Yanjun, TIAN Xue, QIN Yao, YIN Shuishui. Predictive Value of CD44v6 and EGFR Expression in Neoadjuvant Chemotherapy Sensitivity of Stage Ⅱ-Ⅲ Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 937-943.
[2] CHEN Zegang, WANG Yongbing, OU Tao. Neoadjuvant Treatment of Borderline Resectable Pancreatic Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 982-986.
[3] KANG Yikun, YUAN Peng. Advances in Treatment of Triple Negative Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 812-819.
[4] WEI Zongjie, KUANG Youlin, CHEN Yong, WANG Lu, CHEN Xiao, GOU Xin. Efficacy and Adverse Reaction of Tislelizumab Combined with Chemotherapy on Urothelial Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 698-702.
[5] XIE Zhanghong, HUA Qingquan. Research Progress of Ferroptosis in Head and Neck Squamous Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(04): 282-287.
[6] FAN Bingjie, CHANG Yu, LIU Xiyang, ZHANG Mingzhi, ZHANG Lei. Effects of Chemoradiotherapy Versus Chemotherapy Alone on Survival of Patients with Primary Mediastinal Large B-cell Lymphoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(03): 205-212.
[7] LIU Zhenghao, YANG Chunguang, HU Zhiquan. Research Progress on Immunoregulation of Chemotherapeutic Agents[J]. Cancer Research on Prevention and Treatment, 2022, 49(01): 72-77.
[8] LU Mei, YANG Xiaojuan, ZOU Jieya, GUO Rong, WANG Xin, ZHANG Qian, DENG Xuepeng, TAO Jianfen, NIE Jianyun, YANG Zhuangqing. Efficacy Prediction Model for Neoadjuvant Chemotherapy on Breast Cancer Based on Differential Genes Expression[J]. Cancer Research on Prevention and Treatment, 2021, 48(12): 1071-1077.
[9] SUN Chongyuan, ZHAO Dongbing. Characteristics and Risk Factors of Postoperative Complications in Gastric Cancer Patients Treated with Neoadjuvant Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2021, 48(11): 1046-1052.
[10] ?WU Zhaoyang, WANG Shenglin, SHEN Rongkai, CHEN Fei, LIN Jianhua, ZHU Xia, ZHANG Zhenzhen. Association Between Osteogenic Differentiation in Soft Tissue Lump and Clinicopathological Characteristics of Osteosarcoma Patients[J]. Cancer Research on Prevention and Treatment, 2021, 48(09): 859-863.
[11] HE Puyi, LI Xuemei, WANG Yunpeng, XU Bo, WANG Haiyun, ZHANG Jing, PU Weigao, CHEN Hao. Advances in Application of PDT Combined with Multiple Therapies on Unresectable Extrahepatic Cholangiocarcinoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(09): 893-897.
[12] YANG Xiaoli, WANG Cailing, XIA Jin, WANG Junsheng. Clinical Efficacy of Anlotinib Combined with Paclitaxel and Cisplatin as First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(07): 719-722.
[13] KONG Tiandong, CHEN Lu, DUAN Fangfang, WANG Liuyan, ZHOU Hanli, ZHAO Xiaoli, LIU Mengmeng, LIU Danna. Relation Between CD8+T Lymphocyte Infiltration and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2021, 48(05): 484-488.
[14] DAI Yuhong, TAN Ximin, LI Yiming, HUANG Tingting, QIU Hong, QIU Ping. Clinical Analysis of Oxaliplatin-related Thrombocytopenia in Patients with Digestive System Malignancy[J]. Cancer Research on Prevention and Treatment, 2021, 48(05): 497-502.
[15] ZHOU Yajuan, MOU Yanhua, HU Desheng. An Interpretation of CSCO/ASCO International Guideline of Chemotherapy in Combination with Radiotherapy for Definitive-intent Treatment of Stage Ⅱ-Ⅳa Nasopharyngeal Carcinoma in 2021[J]. Cancer Research on Prevention and Treatment, 2021, 48(05): 553-562.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed